Article Details

ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That ... - PR Newswire

Retrieved on: 2022-11-08 21:03:42

Tags for this article:

Click the tags to see associated articles and topics

ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That ... - PR Newswire. View article details on hiswai:

Excerpt

Izokibep is a unique interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies by utilizing high potency ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up